Abstracts claim. Patients were then followed for 30 and 60 days post initiation of COX-2 therapy to evaluate rate of concurrent PPI use. RESULTS: During 2000, 19,318 COX-2 users were identified (1.0% of total membership). Average (median) number of COX-2 prescriptions filled was 3.4 (2) prescriptions per COX-2 patient per year (pppy). Average (median) quantity consumed pppy was 151 (80) capsules for celecoxib and 91 (60) tablets for rofecoxib. Average (median) length of therapy was 148 (86) days pppy. During the study period, 16.7% of patients switched from celecoxib to rofecoxib and 11.9% switched from rofecoxib to celecoxib. Of the 966 previous PPI users identified, 62.3% and 56.8% continued on PPI therapy at 30 and 60 days, respectively, post initiation of COX-2 therapy. CONCLUSIONS: Length of COX-2 therapy for this population was relatively short and the majority of patients who were utilizing a PPI prior to a COX-2 inhibitor continued on PPI therapy.
Abstracts claim. Patients were then followed for 30 and 60 days post initiation of COX-2 therapy to evaluate rate of concurrent PPI use. RESULTS: During 2000, 19,318 COX-2 users were identified (1.0% of total membership). Average (median) number of COX-2 prescriptions filled was 3.4 (2) prescriptions per COX-2 patient per year (pppy). Average (median) quantity consumed pppy was 151 (80) capsules for celecoxib and 91 (60) tablets for rofecoxib. Average (median) length of therapy was 148 (86) days pppy. During the study period, 16.7% of patients switched from celecoxib to rofecoxib and 11.9% switched from rofecoxib to celecoxib. Of the 966 previous PPI users identified, 62.3% and 56.8% continued on PPI therapy at 30 and 60 days, respectively, post initiation of COX-2 therapy. CONCLUSIONS: Length of COX-2 therapy for this population was relatively short and the majority of patients who were utilizing a PPI prior to a COX-2 inhibitor continued on PPI therapy. Evidence for the efficacy of antiresorptive therapies (ART) is convincing for the most part in terms of risk reduction of osteoporotic fractures among high-risk postmenopausal women. Very little information has been published on the frequency of use of ART. OBJECTIVE: To evaluate the probability (P) over time of ART use in women aged 70 years and older who had at least one diagnosed osteoporotic fracture to those without a fracture. METHODS: A cohort design was used, and a random sample of women was collected from RAMQ database. Women were classified in four cohorts, of which two status were defined: those with a fracture and those without fracture in the 5 years prior to cohort entry. The cohort entry was defined as January 95, 96, 98 and 2000. These women were followed up for a year after cohort entry. Several exclusion criteria applied in the 5 years prior cohort entry were used. We stopped to follow women at their 85th birth date. The P of filling at least one prescription of ART during the year following cohort entry was determined using a logistic regression adjusting for age. RESULTS: Mean age and CDS were 78 years old and 3.3. Prior use of ART ranged from 8.9% to 31.2%, and 8.7% to 17.2 for women with and without fracture, respectively. The P of filling at least one prescription of ART excluding HRT from 1995 to 2001 ranged from 1.6% to 28.3% and from 0.5% to 11.3% among women with and without fracture, respectively. The P of filling at least one prescription of HRT ranged from 7.2% to 9.3% for women with and without fracture. CONCLUSION: Our results show an increase of ART use excluding HRT overtime. But, there is still an underuse of ART among women with fracture.
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MISSED OPPORTUNITIES IN PHARMACEUTICAL TREATMENT OF OSTEOPOROSIS IN POST-FRACTURE WOMEN
Wall MJ 1 , Beilfuss CD 1 , Graff JS 1 , McBurney CR 1 , Fendrick AM 2 1 University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2 University of Michigan, Ann Arbor, MI, USA OBJECTIVE: An estimated 9.4 million people in the United States have osteoporosis. The prevalence of vertebral fractures is estimated at between 10% and 25% in women aged 50 and over, with recent longitudinal studies stating that bone loss accelerates with age. The risk for a fracture is highly predictable by an initial fracture (OR = 2.1), leading to great opportunity for prevention of secondary fracture with pharmacotherapy. The purpose of this study is to assess the prevalence of failing to treat women, post-fracture, with pharmaceuticals. METHODS: This is a retrospective database review of a Southeastern Michigan managed care organization's medical claims data from January 1, 1996, and pharmacy claims data from January 1, 1997 1, , through March 21, 2001 . Data include women > 45 years of age before January 1, 2001, with diagnosis of non-traumatic fracture via CPT and ICD-9 codes. Treatment is defined with pharmacy claims data of estrogens, bisphosphonates, raloxifene, or salmon calcitonin. RESULTS: We identified 188 women (mean age at event = 68.0 years) with fracture eligible for treatment, 89 (47%) did not receive treatment before fracture, and 74 (39%) following fracture. The decrease from 89 patients pre-fracture to 74 patients post-fracture failing to receive treatment is the net effect of 6 patients stopping treatment and 21 patients beginning treatment. CONCLUSIONS: The occurrence of a fracture represents an opportunity to prevent further osteoporotic fractures. There is an opportunity to increase patient outcomes to prevent secondary fracture in women 45 years and older. More than one-third of potentially eligible women were not being treated with available medications.
